

CLAIMS

1. A modified IgG comprising:
 - a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 428, numbered according to the EU index as in Kabat,
 - wherein said substitution is a substitution of serine at position 428 with leucine (S428L), and
 - wherein said IgG is an anti-TGF β molecule.
2. The modified IgG of claim 1, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 3.
3. The modified IgG of claim 1, wherein said feline IgG constant domain comprises another substitution, wherein said another substitution is at amino acid residue 434.
4. The modified IgG of claim 3, wherein said another substitution of serine at position 434 with histidine (S434H).
5. The modified IgG of claim 1, wherein the modified IgG having the feline IgG constant domain has a higher affinity for FcRn than an IgG having the wild-type feline IgG constant domain.
6. The modified IgG of claim 1, wherein the modified IgG comprises an Fc constant region having CH2 or CH3 domain, or a combination thereof.
7. The modified IgG of claim 1, wherein the feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.
8. The modified IgG of claim 1, wherein the anti-TGF β molecule comprises a variable heavy (VH) chain having the amino acid sequence set forth in SEQ ID NO.: 45, 55, 65, 75, 85, 95, 105, 115, 125, or 135.
9. The modified IgG of claim 1, wherein the anti-TGF β molecule comprises a variable light (VL) chain having the amino acid sequence set forth in SEQ ID NO.: 47, 57, 67, 77, 87, 97, 107, 117, 127, or 137.

10. A pharmaceutical composition comprising the modified IgG of any one of claims 1-9 and a pharmaceutically acceptable carrier.
11. A fusion molecule comprising the modified IgG of any one of claims 1-9.
12. An immunoglobulin molecule comprising the modified IgG of any one of claims 1-9.
13. A vector comprising the nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO.: 1.
14. An isolated cell comprising the vector of claim 13.
15. A method of manufacturing a molecule, the method comprising: providing the cell of claim 14; and culturing said cell.
16. An IgG Fc region comprising the modified IgG of any one of claims 1-9.
17. Use of an IgG Fc region for increasing a serum half-life of IgG in a cat, wherein said Fc region comprising the modified IgG of any one of claims 1-9.